Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC By Ogkologos - August 31, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the third pre-specified interim analysis of the OlympiA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide Aiming to Support Cancer Research, ESMO Calls on the European Council to Allocate a Budget of at Least €220 Billion to Horizon Europe New Translations of the ESMO Patient Guides Available in Estonian MOST POPULAR For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions June 3, 2021 Understanding FDA Emergency Use Authorization January 21, 2021 ¿Las gammagrafías óseas muestran el cáncer? April 28, 2021 EMA Recommends Extending Indications for Durvalumab July 17, 2025 Load more HOT NEWS Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment... Breaking the silence: when cancer steals your voice New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers
